Last updated: April 24, 2026
QNASL (beclomethasone dipropionate) Suppliers: Who Makes the Products in the Market?
QNASL is a branded intranasal corticosteroid (active: beclomethasone dipropionate). Commercial supply in the U.S. and globally is defined by (1) the approved drug-product/labeler of record on the U.S. market and (2) the manufacturing sites credited for finished-dose product production. The supplier set is therefore anchored to the FDA’s National Drug Code (NDC) directory entries and the underlying application/manufacturer listings for the marketed label.
Who are the “suppliers” for QNASL in practice (U.S. labeler and manufacturing sites)?
The operational supplier list is the set of companies appearing as labeler (application holder or commercial labeler) and those listed as manufacturers for the finished dosage form for each marketed NDC strength and pack configuration.
| QNASL attribute |
What “supplier” means here |
Where it is captured |
| Labeler / applicant |
Company on the labeler line for the NDC |
FDA NDC Directory |
| Finished dosage manufacturing site |
Company and plant listed as the manufacturer for the NDC |
FDA NDC Directory / associated application records |
| Strength and NDC mapping |
Differing NDCs can map to different manufacturing arrangements |
FDA NDC Directory |
Market-facing supplier identification requires NDC-by-NDC validation. A single brand does not guarantee one site across all presentations.
What are the specific QNASL NDCs to anchor supplier mapping?
Supplier mapping is NDC-specific. Without a complete NDC list (all strengths and package sizes) for QNASL in a given geography, supplier attribution can be incomplete because different NDCs can point to different manufacturers.
What supplier companies appear for QNASL based on FDA listings?
A definitive, complete supplier table requires pulling the exact QNASL NDC Directory entries (labeler and manufacturing sites) and enumerating them by strength and package type. The FDA’s NDC Directory is the source of record for those fields.
Because the necessary NDC Directory data for QNASL was not included in the input provided here, a complete and accurate supplier roster (labeler and manufacturing sites) cannot be produced.
Key Takeaways
- QNASL supplier identification must be anchored to FDA NDC Directory labeler and manufacturer listings, which are NDC-specific.
- A complete supplier list requires enumerating all QNASL strengths and pack configurations by NDC to avoid omissions or misattribution.
- Without the NDC-level inputs, any named supplier list would risk being incomplete or wrong.
FAQs
-
What is the correct way to identify QNASL suppliers for sourcing?
Use the FDA NDC Directory fields for labeler and manufacturer tied to each QNASL NDC.
-
Are QNASL suppliers the same across all strengths and package sizes?
Not necessarily. Different NDCs can map to different manufacturing arrangements.
-
Does the “labeler” equal the manufacturing company?
Often they differ. The labeler is the NDC label-holder/registrant, while manufacturing can be performed at separate sites.
-
Where does supplier attribution come from for FDA-approved products?
FDA NDC Directory entries and linked application/manufacturer records.
-
Can generic “supplier” lists be used instead of NDC mapping?
Only for high-level research. For sourcing and regulatory diligence, NDC-linked manufacturer and labeler data is required.
References (APA)
[1] U.S. Food & Drug Administration. National Drug Code (NDC) Directory. https://www.accessdata.fda.gov/scripts/cder/ndc/
